The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.

BACKGROUND The enzyme 5-lipoxygenase catalyzes the metabolism of arachidonic acid to form products that have been implicated in the airway obstruction of asthma. We hypothesized that if products of the 5-lipoxygenase pathway are important in mediating this obstruction, then prevention of their formation should decrease the severity of an induced asthmatic response. METHODS In a randomized, double-blind, placebo-controlled, crossover study, we examined the effect of A-64077, a 5-lipoxygenase inhibitor, on the bronchoconstriction induced by hyperventilation of cold, dry air in 13 patients with asthma. The completeness of 5-lipoxygenase inhibition was confirmed by examining the profile of eicosanoids produced in whole blood ex vivo after activation with the calcium ionophore A-23187. RESULTS A-64077 decreased the mean (+/- SEM) ionophore-induced synthesis of leukotriene B4, a 5-lipoxygenase product, by 74 percent (from 265.3 +/- 30.3 to 69.5 +/- 21.5 ng per milliliter, P less than 0.001), but it did not affect the ionophore-induced synthesis of thromboxane B2, a cyclooxygenase metabolite of arachidonic acid (80.0 +/- 17.1 ng per milliliter before A-64077 vs. 75.8 +/- 14.3 ng per milliliter after A-64077). In concert with the selective inhibition of 5-lipoxygenase by A-64077, the amount of cold, dry air (expressed as respiratory heat exchange) required to reduce the forced expiratory volume in one second by 10 percent was increased by 47 percent after A-64077 (3.0 kJ per minute for placebo vs. 4.4 kJ per minute for A-64077, P less than 0.002). Similar results were obtained when minute ventilation was used as an indicator of outcome (27.5 liters per minute for placebo vs. 39.8 liters per minute for A-64077, P less than 0.005). CONCLUSIONS Selective inhibition of 5-lipoxygenase by A-64077 is associated with a significant amelioration of the asthmatic response to cold, dry air, suggesting that 5-lipoxygenase products are involved in this response. This approach may be useful in the treatment of asthma.

[1]  A. Wardlaw,et al.  Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. , 1989, The Journal of allergy and clinical immunology.

[2]  C. Dollery,et al.  URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITIS , 1989, The Lancet.

[3]  E. Israel,et al.  Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. , 1989, The American review of respiratory disease.

[4]  J. Malo,et al.  Theophylline minimally inhibits bronchoconstriction induced by dry cold air inhalation in asthmatic subjects. , 1988, The American review of respiratory disease.

[5]  T. Nagakura,et al.  Role of chemical mediators after antigen and exercise challenge in children with asthma. , 1988, The Journal of allergy and clinical immunology.

[6]  M. Chan-yeung,et al.  Release of leukotrienes in patients with bronchial asthma. , 1988, The Journal of allergy and clinical immunology.

[7]  J. Drazen.  Comparative Contractile Responses to Sulfidopeptide Leukotrienes in Normal and Asthmatic Human Subjects , 1988, Annals of the New York Academy of Sciences.

[8]  C. Dollery,et al.  Oral nafazatrom in man: effect on inhaled antigen challenge. , 1987, British journal of clinical pharmacology.

[9]  K. Austen,et al.  Critical considerations in the development of an assay for sulfidopeptide leukotrienes in plasma. , 1987, Prostaglandins.

[10]  M. Fujimura,et al.  Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. , 1986, Thorax.

[11]  S. Holgate,et al.  Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. , 1986, Thorax.

[12]  P. O'Byrne,et al.  Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. , 1986, The New England journal of medicine.

[13]  E. R. Mcfadden,et al.  Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. , 1986, The Journal of clinical investigation.

[14]  M. Belman,et al.  The Case of the Moving Intrathoracic Mass , 1985 .

[15]  N. Barnes,et al.  Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. , 1984, Thorax.

[16]  J. Shelhamer,et al.  Human airway monohydroxyeicosatetraenoic acid generation and mucus release. , 1983, The Journal of clinical investigation.

[17]  E. R. Mcfadden,et al.  Respiratory heat and water exchange: physiological and clinical implications. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[18]  Robert A. Lewis,et al.  Bronchoconstrictor effects of leukotriene C in humans. , 1982, Science.

[19]  M. Dixon,et al.  BRONCHOCONSTRICTION PRODUCED IN MAN BY LEUKOTRIENES C AND D , 1981, The Lancet.

[20]  M. A. Bray,et al.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes , 1980, Nature.

[21]  S. Anderson,et al.  An evaluation of pharmacotherapy for exercise-induced asthma. , 1979, The Journal of allergy and clinical immunology.

[22]  R. Murphy,et al.  Leukotriene C: a slow-reacting substance from murine mastocytoma cells. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. R. Mcfadden,et al.  Hyperpnea and heat flux: initial reaction sequence in exercise-induced asthma. , 1979, Journal of applied physiology: respiratory, environmental and exercise physiology.